Focused On-demand Library for Alkylated DNA repair protein alkB homolog 8

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96BT7

UPID:

ALKB8_HUMAN

Alternative names:

Probable alpha-ketoglutarate-dependent dioxygenase ABH8; S-adenosyl-L-methionine-dependent tRNA methyltransferase ABH8; tRNA (carboxymethyluridine(34)-5-O)-methyltransferase ABH8

Alternative UPACC:

Q96BT7; B1Q2M0; B4DEF6; Q8N989

Background:

Alkylated DNA repair protein alkB homolog 8, also known as ABH8, plays a crucial role in the post-transcriptional modification of tRNA. It catalyzes the methylation and hydroxylation of 5-carboxymethyl uridine at the wobble position of the anticodon loop in tRNA, impacting protein synthesis and cellular response to DNA damage. ABH8 shows a preference for tRNA(Arg) and tRNA(Glu), and is essential for normal cell survival post-DNA damage.

Therapeutic significance:

ABH8's involvement in Intellectual developmental disorder, autosomal recessive 71, underscores its potential as a therapeutic target. Understanding ABH8's role could open doors to novel strategies for treating intellectual disabilities and enhancing DNA damage response.